IDXX vs. NVO: A Head-to-Head Stock Comparison

Updated on August 28, 2025

Here’s a clear look at IDXX and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

IDXX is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	IDXX	NVO
Company Name	IDEXX Laboratories, Inc.	Novo Nordisk A/S
Country	United States	Denmark
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Equipment & Supplies	Pharmaceuticals
Market Capitalization	51.31 billion USD	244.20 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	June 21, 1991	April 30, 1981
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of IDXX and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

IDXX vs. NVO: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	IDXX	NVO
5-Day Price Return	0.73%	4.72%
13-Week Price Return	27.04%	-17.05%
26-Week Price Return	42.21%	-37.87%
52-Week Price Return	30.43%	-60.23%
Month-to-Date Return	20.03%	15.71%
Year-to-Date Return	55.13%	-41.70%
10-Day Avg. Volume	0.44M	6.68M
3-Month Avg. Volume	0.65M	6.63M
3-Month Volatility	60.25%	65.20%
Beta	1.59	1.52

Profitability

Return on Equity (TTM)

IDXX

64.42%

Health Care Equipment & Supplies Industry

Max: 34.53%
Q3: 19.38%
Median: 9.52%
Q1: 4.86%
Min: -7.58%

IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

NVO

77.86%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

IDXX vs. NVO: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

IDXX

24.41%

Health Care Equipment & Supplies Industry

Max: 23.34%
Q3: 13.06%
Median: 9.53%
Q1: 5.96%
Min: -3.87%

IDXX’s Net Profit Margin of 24.41% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

NVO

35.61%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

IDXX vs. NVO: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

IDXX

31.09%

Health Care Equipment & Supplies Industry

Max: 29.44%
Q3: 17.80%
Median: 13.95%
Q1: 8.73%
Min: -3.56%

IDXX’s Operating Profit Margin of 31.09% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

NVO

45.78%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

IDXX vs. NVO: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	IDXX	NVO
Return on Equity (TTM)	64.42%	77.86%
Return on Assets (TTM)	29.89%	24.22%
Net Profit Margin (TTM)	24.41%	35.61%
Operating Profit Margin (TTM)	31.09%	45.78%
Gross Profit Margin (TTM)	61.54%	83.95%

Financial Strength

Current Ratio (MRQ)

IDXX

1.11

Health Care Equipment & Supplies Industry

Max: 4.90
Q3: 3.05
Median: 2.14
Q1: 1.49
Min: 0.86

IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NVO

0.78

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

IDXX vs. NVO: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

IDXX

0.76

Health Care Equipment & Supplies Industry

Max: 1.49
Q3: 0.71
Median: 0.45
Q1: 0.14
Min: 0.00

IDXX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

NVO

0.59

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

IDXX vs. NVO: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

IDXX

49.24

Health Care Equipment & Supplies Industry

Max: 58.29
Q3: 25.56
Median: 9.06
Q1: 3.60
Min: -28.92

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

NVO

149.07

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

IDXX vs. NVO: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	IDXX	NVO
Current Ratio (MRQ)	1.11	0.78
Quick Ratio (MRQ)	0.75	0.56
Debt-to-Equity Ratio (MRQ)	0.76	0.59
Interest Coverage Ratio (TTM)	49.24	149.07

Growth

Revenue Growth

IDXX vs. NVO: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

IDXX vs. NVO: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.05%
Q3: 1.76%
Median: 0.71%
Q1: 0.00%
Min: 0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NVO

3.30%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

IDXX vs. NVO: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 72.47%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NVO

61.60%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

IDXX vs. NVO: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	IDXX	NVO
Dividend Yield (TTM)	0.00%	3.30%
Dividend Payout Ratio (TTM)	0.00%	61.60%

Valuation

Price-to-Earnings Ratio (TTM)

IDXX

51.66

Health Care Equipment & Supplies Industry

Max: 73.48
Q3: 51.69
Median: 34.31
Q1: 25.74
Min: 11.47

IDXX’s P/E Ratio of 51.66 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVO

13.91

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

IDXX vs. NVO: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

IDXX

12.61

Health Care Equipment & Supplies Industry

Max: 9.53
Q3: 5.26
Median: 3.39
Q1: 2.13
Min: 0.00

With a P/S Ratio of 12.61, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

NVO

4.95

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

IDXX vs. NVO: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

IDXX

29.57

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 5.98
Median: 3.48
Q1: 2.43
Min: 0.69

At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

NVO

8.87

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

IDXX vs. NVO: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	IDXX	NVO
Price-to-Earnings Ratio (TTM)	51.66	13.91
Price-to-Sales Ratio (TTM)	12.61	4.95
Price-to-Book Ratio (MRQ)	29.57	8.87
Price-to-Free Cash Flow Ratio (TTM)	65.76	23.46